Pfizer's blockbuster-to-be Vyndaqel is too costly for heart patients, study suggests

19th June 2020 Uncategorised 0

Pfizer’s blockbuster-to-be Vyndaqel is too costly for heart patients, study suggests
aliu
Fri, 06/19/2020 – 11:05




More: Pfizer's blockbuster-to-be Vyndaqel is too costly for heart patients, study suggests
Source: fierce